Gilead Sciences, Inc. is downgraded to Hold due to uncertainty on the Arcellx acquisition and cell therapy portfolio challenges. Read more on GILD stock here.

Once a loan is paid off, banks, credit unions and dealers can release the title immediately. Leaders say this benefits ...